PVLA PALVELLA THERAPEUTICS INC

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA)  (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025.

Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update.

To access the live webcast of the call with slides, please click or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this , and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at .

About Palvella Therapeutics

Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit  or follow Palvella on  or  (formerly known as Twitter).

QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency.

Contact Information

Investors

Wesley H. Kaupinen

Founder and CEO, Palvella Therapeutics

Media

Marcy Nanus

Managing Partner, Trilon Advisors, LLC



EN
18/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALVELLA THERAPEUTICS INC

 PRESS RELEASE

Palvella Therapeutics to Host Full Year 2024 Financial Results Confere...

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA)  (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, ...

 PRESS RELEASE

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcar...

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET. A live webcast of the presentation will be available on the  section of P...

 PRESS RELEASE

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN...

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic malformations (microcystic LMs) Company remains on track to report top line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of microcystic LMs, in Q1 2026 QTORIN™ rapamycin has the...

 PRESS RELEASE

Palvella Therapeutics Announces Publication of Results from Phase 2 Cl...

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies Publication reports 100% of participants were either “Much Improved” or “Very Much Improved” as rated by the Clinician Global Impression of Change following 12-weeks of QTORIN™ rapamycin FDA previously granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation to QTORIN™ rapamycin for microcystic lymphatic malformations (m...

 PRESS RELEASE

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA ...

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of cutaneous venous malformations (cutaneous VMs) to enroll approximately 15 subjects at leading vascular anomaly centers across the U.S. Cutaneous VMs are a serious and lifelong genetic disease that can result in substantial morbidity and functional impairment of th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch